1593969-81-3

Basic information

• Product Name: N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester
• Synonyms: N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester;tert-butyl N-[(3S,5S)-5-fluoropiperidin-3-yl]carbamate
• CAS NO: 1593969-81-3
• Molecular Formula: C10H19FN2O2
• Molecular Weight: 218.2684632
• EINECS: -0
• Mol File: 1593969-81-3.mol

Chemical Properties

• Boiling Point: 313.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.68±0.40(Predicted)
• CAS DataBase Reference: N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester(1593969-81-3)
• EPA Substance Registry System: N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester(1593969-81-3)

Safety Data

• Hazardous Substances Data: 1593969-81-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to be incorporated into complex molecular structures, enhancing their therapeutic properties and effectiveness.
Used in Chemical Research:
In the field of chemical research, N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester serves as a valuable building block for the development of new molecules with potential applications in various industries, including materials science, agrochemicals, and pharmaceuticals.
Used in the Preparation of bisheterocyclic inhibitors of PAD4:
N-[(3S,5S)-5-fluoro-3-piperidinyl]-, 1,1-dimethylethyl ester is used as a key component in the preparation of bisheterocyclic inhibitors of PAD4 (peptidylarginine deiminase 4), an enzyme involved in various biological processes. These inhibitors can potentially be used for the treatment of diseases associated with the dysregulation of PAD4 activity.

Upstream product

• 1187055-37-3 (3S,5S)-benzyl 3-(tert-butoxycarbonylamino)-5-fluoropiperidine-1-carboxylate 
• 1318129-90-6 ((2R,4S)-4-amino-1-tritylpyrrolidin-2-yl)methanol 
• 536746-99-3 (2R,4R)-methyl 4-hydroxy-1-tritylpyrrolidine-2-carboxylate 
• 1052715-31-7 (3S,5R)-benzyl 3-((tert-butoxycarbonyl)amino)-5-fluoropiperidine-1-carboxylate 
• 1405129-28-3 (3R,5R)-benzyl 3-fluoro-5-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 1052715-30-6 (3S,5R)-benzyl 3-azido-5-fluoropiperidine-1-carboxylate 
• 51-35-4 4R-4-hydroxyproline 
• 1611480-88-6 N-((3S,5S)-5-(hydroxymethyl)-1-tritylpyrrolidin-3-yl)benzamide 
• 1611481-36-7 ((2S,4S)-4-amino-1-tritylpyrrolidin-2-yl)methanol 
• 129430-93-9 (2S,4S)-methyl 4-hydroxy-1-tritylpyrrolidine-2-carboxylate 
• 81102-38-7 cis-L-hydroxyproline methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1611480-82-0 (2S,4R)-methyl 4-azido-1-tritylpyrrolidine-2-carboxylate 
• 1611481-35-6 ((2S,4R)-4-amino-1-tritylpyrrolidin-2-yl)methanol 

Downstream Products

• 1611480-96-6 tert-butyl (3S,5S)-1-benzoyl-5-fluoropiperidin-3-ylcarbamate 
• 1611480-97-7 ((3S,5S)-3-amino-5-fluoropiperidin-1-yl)(phenyl)methanone 
• 1611481-03-8 tert-butyl (3S,5S)-5-fluoro-1-(4-methoxybenzoyl)piperidin-3-ylcarbamate 
• 1611481-04-9 ((3S,5S)-3-amino-5-fluoropiperidin-1-yl)(4-methoxyphenyl)methanone 
• 1611481-05-0 ((3S,5S)-3-amino-5-fluoropiperidin-1-yl)(3-methoxyphenyl)methanone 
• 1611481-06-1 ((3S,5S)-3-amino-5-fluoropiperidin-1-yl)(2-methoxyphenyl)methanone 
• 1611481-10-7 ((3S,5S)-3-amino-5-fluoropiperidin-1-yl)(3-nitrophenyl)methanone 
• 1611481-11-8 ((3S,5S)-3-amino-5-fluoropiperidin-1-yl)(2-nitrophenyl)methanone 
• 1611487-95-6 (3S,5S)-(9H-fluoren-9-yl)methyl 3-amino-5-fluoropiperidine-1-carboxylate hydrochloride 
• 1611487-97-8 N-((3S,5S)-5-fluoropiperidin-3-yl)-4-nitrobenzamide 
• 1611487-98-9 N-((3S,5S)-5-fluoropiperidin-3-yl)-3-nitrobenzamide 
• 1611487-99-0 N-((3S,5S)-5-fluoropiperidin-3-yl)-2-nitrobenzamide 
• 1611481-00-5 C₁₇H₂₃FN₂O₃ 
• 1611481-01-6 ((3S,5R)-3-amino-5-fluoropiperidin-1-yl)(phenyl)methanone 

Relevant articles and documents

PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Enantioselective synthesis and physicochemical properties of libraries of 3-amino- and 3-amidofluoropiperidines

The enantioselective syntheses of 3-amino-5-fluoropiperidines and 3-amino-5,5-difluoropiperidines were developed using the ring enlargement of prolinols to access libraries of 3-amino- and 3-amidofluoropiperidines. The study of the physicochemical properties revealed that fluorine atom(s) decrease(s) the pKa and modulate(s) the lipophilicity of 3-aminopiperidines. The relative stereochemistry of the fluorine atoms with the amino groups at C3 on the piperidine core has a small effect on the pK a due to conformationnal modifications induced by fluorine atom(s). In the protonated forms, the C-F bond is in an axial position due to a dipole-dipole interaction between the N-H+ and C-F bonds. Predictions of the physicochemical properties using common software appeared to be limited to determine correct values of pKa and/or differences of pK a between cis- and trans-3-amino-5-fluoropiperidines.

BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS

The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

Pim kinase inhibitors and methods of their use

The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.

PIM KINASE INHIBITORS AND METHODS OF THEIR USE

The present invention relates to new compounds of Formulas (I) and (II), their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmac